{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T23:33:19Z","timestamp":1772148799382,"version":"3.50.1"},"reference-count":15,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2004,8,27]],"date-time":"2004-08-27T00:00:00Z","timestamp":1093564800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Transplantation"],"published-print":{"date-parts":[[2004,12]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> Micafungin, a new candin antifungal drug, has a good safety profile and a significant therapeutic effect against <jats:italic>Candida<\/jats:italic> and <jats:italic>Aspergillus<\/jats:italic>. Little is known, however, about the optimal prophylactic dosage and the disposition of micafungin in liver transplant recipients, or about the effect of continuous venovenous hemodialysis (CVVH) on the pharmacokinetics of micafungin. Six living donor liver transplant patients were enrolled in this study. The mean <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> and <jats:italic>C<\/jats:italic><jats:sub>min<\/jats:sub> (trough) values of micafungin in plasma were 6.31\u2003\u00b1\u20031.08 and 1.65\u2003\u00b1\u20030.54\u2003<jats:italic>\u03bc<\/jats:italic>g\/mL, respectively. The mean elimination half\u2010life (<jats:italic>t<\/jats:italic><jats:sub>1\/2<\/jats:sub>) and mean area under the curve up to 12\u2003h post\u2010dosing (AUC 0\u201312\u2003h) were 13.63\u2003\u00b1\u20032.77\u2003h and 50.04\u2003\u00b1\u20036.48\u2003<jats:italic>\u03bc<\/jats:italic>g\u00b7h\/mL, respectively. The concentrations of micafungin at the inlet and outlet of the dialyzer were very similar. The mean (\u00b1SD) ratio of micafungin concentrations at the inlet and outlet of the dialyzer (coutlet\/cinlet) and the clearance of micafungin were 0.96\u2003\u00b1\u20030.04 and 0.054\u2003\u00b1\u20030.04\u2003mL\/min\/kg, respectively. The amount in the ultrafiltrate was 1.0\u2003mg. Micafungin effectively prevents systemic fungal infection in patients who have undergone liver transplantation. No significant differences were observed in the disposition of micafungin in recipients, and the therapeutic drug level can be achieved by administration of micafungin at a dosage of 40\u201350\u2003mg\/d. The CVVH had little effect on micafungin kinetics, and no dose adjustment or modification of dosing interval was needed during CVVH.<\/jats:p>","DOI":"10.1111\/j.1399-0012.2004.00272.x","type":"journal-article","created":{"date-parts":[[2004,10,28]],"date-time":"2004-10-28T18:53:37Z","timestamp":1098989617000},"page":"676-680","source":"Crossref","is-referenced-by-count":42,"title":["Optimal prophylactic dosage and disposition of micafungin in living donor liver recipients"],"prefix":"10.1111","volume":"18","author":[{"given":"Satoshi","family":"Kishino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Shimamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki, Satoru","family":"Furukawa Todo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,9,29]]},"reference":[{"key":"e_1_2_10_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-198803000-00006"},{"key":"e_1_2_10_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1991.01410260033005"},{"key":"e_1_2_10_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/19.4.684"},{"key":"e_1_2_10_5_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.5-2-120"},{"key":"e_1_2_10_6_2","doi-asserted-by":"crossref","first-page":"674","DOI":"10.7164\/antibiotics.52.674","article-title":"FK\u2010463, a novel water\u2010soluble echinocandin lipopeptide: synthesis and antifungal activity","volume":"52","author":"Tomishima M","year":"1999","journal-title":"J Antibiot"},{"key":"e_1_2_10_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.12.3322-3327.2001"},{"key":"e_1_2_10_8_2","doi-asserted-by":"publisher","DOI":"10.1248\/bpb1978.4.879"},{"key":"e_1_2_10_9_2","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1128\/AAC.44.3.614-618.2000","article-title":"Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidadis and aspergillosis","volume":"44","author":"Ikeda F","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_10_10_2","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1128\/AAC.41.9.1957","article-title":"Comparison of the in vitro activities of the echinocandin LY 303366, the pneumocandin MK\u20100991, and fluconazole against Candida species and Cryptococcus neoformans","volume":"41","author":"Krishnarao TV","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_10_11_2","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1128\/AAC.44.6.1728-1730.2000","article-title":"Efficacy of FK463, a (1,3)\u2010b\u2010D\u2010glucan synthase inhibitor in disseminated azol\u2010resistant Candida albicans infection in mice","volume":"44","author":"Maesaki S","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_10_12_2","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1128\/AAC.44.3.619-621.2000","article-title":"Efficacy of FK406, a new lipopeptide antifungal agent in mouse models of pulmonary aspergillosis","volume":"44","author":"Matsumoto S","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"e_1_2_10_13_2","first-page":"43","article-title":"Minimum effective concentrations of micafungin for the treatment of disseminated Candida albicans infection and pulmonary Aspergillus fumigatus infection in mouse","volume":"50","author":"Wakai Y","year":"2002","journal-title":"Jpn J Chemother"},{"key":"e_1_2_10_14_2","volume-title":"Pharmacokinetics of FK463, a Novel Echinocandin Analogue, in Elderly and Non\u2010Elderly Subjects. Inthe Program and Abstract of the Forty\u2010First Interscience Conference on Antimicrobial Agents and Chemotherapy","author":"Mukai T","year":"2001"},{"key":"e_1_2_10_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(01)36203-3"},{"key":"e_1_2_10_16_2","volume-title":"Phase I Study of FK463, a New Antifungal Agent, in Healthy Adult Male Volunteers. In Program and Abstract of the Thirty\u2010Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy","author":"Azuma J","year":"1998"}],"container-title":["Clinical Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-0012.2004.00272.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-0012.2004.00272.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T17:12:31Z","timestamp":1697217151000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-0012.2004.00272.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9,29]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["10.1111\/j.1399-0012.2004.00272.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-0012.2004.00272.x","archive":["Portico"],"relation":{},"ISSN":["0902-0063","1399-0012"],"issn-type":[{"value":"0902-0063","type":"print"},{"value":"1399-0012","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9,29]]}}}